Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
233.8
USD
|
-0.89%
|
|
-1.71%
|
+6.35%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,865
|
6,746
|
9,731
|
12,674
|
10,333
|
11,005
|
-
|
-
|
Enterprise Value (EV)
1 |
3,977
|
5,711
|
9,637
|
12,513
|
8,039
|
7,700
|
6,869
|
5,458
|
P/E ratio
|
-36.9
x
|
13.2
x
|
21.5
x
|
18.5
x
|
11.1
x
|
9.76
x
|
9.5
x
|
8.99
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.67
x
|
4.55
x
|
5.77
x
|
6.55
x
|
4.44
x
|
4.08
x
|
3.9
x
|
3.56
x
|
EV / Revenue
|
2.74
x
|
3.85
x
|
5.72
x
|
6.46
x
|
3.45
x
|
2.85
x
|
2.44
x
|
1.76
x
|
EV / EBITDA
|
-28.1
x
|
8.87
x
|
15.9
x
|
12.1
x
|
6.49
x
|
5.51
x
|
4.78
x
|
3.53
x
|
EV / FCF
|
-13.7
x
|
8.2
x
|
20.2
x
|
18.9
x
|
10.8
x
|
7.2
x
|
5.97
x
|
4.11
x
|
FCF Yield
|
-7.3%
|
12.2%
|
4.95%
|
5.3%
|
9.3%
|
13.9%
|
16.8%
|
24.3%
|
Price to Book
|
1.39
x
|
1.99
x
|
2.67
x
|
2.67
x
|
1.73
x
|
1.6
x
|
1.38
x
|
1.21
x
|
Nbr of stocks (in thousands)
|
43,881
|
44,441
|
45,037
|
45,577
|
46,994
|
47,059
|
-
|
-
|
Reference price
2 |
88.08
|
151.8
|
216.1
|
278.1
|
219.9
|
233.8
|
233.8
|
233.8
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/24/22
|
2/22/23
|
2/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,449
|
1,483
|
1,686
|
1,936
|
2,328
|
2,699
|
2,818
|
3,094
|
EBITDA
1 |
-141.7
|
643.5
|
605.8
|
1,031
|
1,238
|
1,398
|
1,437
|
1,547
|
EBIT
1 |
-187.6
|
593.6
|
555.9
|
979.7
|
1,185
|
1,436
|
1,475
|
1,601
|
Operating Margin
|
-12.95%
|
40.02%
|
32.98%
|
50.6%
|
50.91%
|
53.19%
|
52.35%
|
51.75%
|
Earnings before Tax (EBT)
1 |
-165
|
638.9
|
593.9
|
950.6
|
1,274
|
1,490
|
1,582
|
1,689
|
Net income
1 |
-104.5
|
514.8
|
475.8
|
727.3
|
984.8
|
1,195
|
1,231
|
1,304
|
Net margin
|
-7.21%
|
34.71%
|
28.23%
|
37.56%
|
42.31%
|
44.29%
|
43.67%
|
42.15%
|
EPS
2 |
-2.390
|
11.54
|
10.06
|
15.00
|
19.81
|
23.96
|
24.61
|
26.01
|
Free Cash Flow
1 |
-290.3
|
696.4
|
477.4
|
663.7
|
747.6
|
1,070
|
1,151
|
1,326
|
FCF margin
|
-20.04%
|
46.95%
|
28.32%
|
34.28%
|
32.12%
|
39.65%
|
40.83%
|
42.88%
|
FCF Conversion (EBITDA)
|
-
|
108.22%
|
78.8%
|
64.37%
|
60.38%
|
76.53%
|
80.09%
|
85.77%
|
FCF Conversion (Net income)
|
-
|
135.28%
|
100.34%
|
91.26%
|
75.91%
|
89.52%
|
93.49%
|
101.73%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/24/22
|
2/22/23
|
2/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
444.7
|
415.2
|
461.9
|
466.9
|
516
|
491.5
|
506.9
|
596.5
|
609.4
|
614.7
|
623.3
|
688.3
|
712.7
|
719.2
|
-
|
EBITDA
|
241.1
|
182.4
|
300.5
|
214.5
|
327.2
|
188.8
|
297.7
|
326.3
|
340.3
|
273.8
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
228.7
|
169.8
|
288
|
201.8
|
314.3
|
175.6
|
284.4
|
313.4
|
327
|
260.1
|
335.2
|
371.2
|
383.5
|
377.3
|
-
|
Operating Margin
|
51.43%
|
40.9%
|
62.35%
|
43.22%
|
60.91%
|
35.73%
|
56.11%
|
52.54%
|
53.66%
|
42.31%
|
53.77%
|
53.92%
|
53.8%
|
52.46%
|
-
|
Earnings before Tax (EBT)
1 |
204.4
|
140.5
|
308.7
|
150.6
|
312.5
|
178.8
|
291.9
|
335.2
|
351.8
|
295.4
|
358.3
|
380
|
394.5
|
387.8
|
-
|
Net income
1 |
162.7
|
112.2
|
239.9
|
116
|
239.3
|
132.1
|
240.9
|
259.2
|
267.6
|
217.1
|
280.6
|
308.1
|
319.6
|
306.4
|
-
|
Net margin
|
36.59%
|
27.02%
|
51.94%
|
24.84%
|
46.38%
|
26.88%
|
47.52%
|
43.45%
|
43.91%
|
35.32%
|
45.01%
|
44.75%
|
44.84%
|
42.6%
|
-
|
EPS
2 |
3.420
|
2.350
|
5.030
|
2.410
|
4.910
|
2.670
|
4.860
|
5.240
|
5.380
|
4.360
|
5.642
|
6.079
|
6.306
|
5.988
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/3/21
|
2/24/22
|
5/4/22
|
8/3/22
|
11/2/22
|
2/22/23
|
5/3/23
|
8/2/23
|
11/1/23
|
2/21/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
112
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
1,035
|
94.8
|
161
|
2,294
|
3,305
|
4,136
|
5,547
|
Leverage (Debt/EBITDA)
|
-0.7876
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-290
|
696
|
477
|
664
|
748
|
1,070
|
1,151
|
1,327
|
ROE (net income / shareholders' equity)
|
-3.75%
|
16.7%
|
12.9%
|
16.6%
|
18.3%
|
16.8%
|
15.2%
|
13.5%
|
ROA (Net income/ Total Assets)
|
15.6%
|
12.1%
|
9.85%
|
13%
|
14.9%
|
14.8%
|
13.7%
|
12.5%
|
Assets
1 |
-671.4
|
4,264
|
4,832
|
5,607
|
6,606
|
8,082
|
8,965
|
10,405
|
Book Value Per Share
2 |
63.40
|
76.40
|
81.00
|
104.0
|
127.0
|
146.0
|
170.0
|
193.0
|
Cash Flow per Share
2 |
-4.720
|
16.90
|
12.60
|
16.50
|
19.70
|
23.50
|
23.90
|
28.70
|
Capex
1 |
83.7
|
59.3
|
121
|
139
|
230
|
211
|
242
|
200
|
Capex / Sales
|
5.78%
|
4%
|
7.17%
|
7.17%
|
9.9%
|
7.83%
|
8.59%
|
6.46%
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/24/22
|
2/22/23
|
2/21/24
|
-
|
-
|
-
|
Last Close Price
233.8
USD Average target price
285.5
USD Spread / Average Target +22.08% Consensus |
1st Jan change
|
Capi.
|
---|
| +6.35% | 11B | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | -16.98% | 10.07B |
Other Biotechnology & Medical Research
|